Immunoglobulin News and Research

RSS

New study may shed light on inflammatory bowel disease

Researchers have found an unexpected synergy between a T-cell stimulatory protein -- the ICOS ligand -- and interleukin-10, an immunoregulatory cytokine, to prevent inflammatory bowel disease in mice.

26 Mar 2021

Study observes correlation between COVID-19 mortality and autoantibodies in corticosteroid treated patients

Corticosteroid anti-inflammatory drugs have been applied to COVID-19 patients over the course of the pandemic, though the results are mixed. In a recent study, the outcomes for such patients are collated, demonstrating a striking correlation between the development of autoantibodies and mortality.

25 Mar 2021

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

A new study, which was released on the bioRxiv* preprint server, shows the differential effect that a standard vaccine protocol may have on individuals, based on their history of prior infection with the virus.

25 Mar 2021

Reduced mRNA COVID-19 vaccine response in nursing home residents

A recent study has examined the response of nursing home residents who were naïve to SARS-CoV-2 infection following vaccination by the mRNA BNT162b2 model from Pfizer-BioNTech.

24 Mar 2021

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

A new preprint study led by Shawn S-C. Li from Western University in Ontario, Canada, provides evidence of epitope-specific antibody responses and designed a test to measure this in relation to disease severity and outcome after infection.

24 Mar 2021

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

A recent study by researchers from Philadelphia, currently available on the medRxiv preprint server, shows that individuals with prior infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit substantial immune memory and develop a robust response to the first dose of an mRNA vaccine.

23 Mar 2021

Study suggests SARS-CoV-2 antibodies in breast milk are robust, neutralizing and durable

A new study addresses the issue of passive immunity to SARS-CoV-2 for newborns via breast milk.

23 Mar 2021

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

In a paper recently uploaded to the preprint server bioRxiv by Tauzin et al. (March 18th, 2021) the ability of a single dose of mRNA vaccine to induce humoral and T cell responses against mutated variants are demonstrated and found to be reinforced in individuals with a history of COVID-19.

22 Mar 2021

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

New preclinical research led by Wensheng Wei from Peking University in China has proposed the development of a circular RNA vaccine. Their findings showed the circular RNA vaccine creates neutralizing antibodies and strong T-cell responses against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

21 Mar 2021

New proteomics method helps confirm COVID-19 transmission from mother to fetus

Researchers from Skoltech were part of a research consortium studying a case of vertical COVID-19 transmission from mother to her unborn child that resulted in major complications in the pregnancy, premature birth and death of the child.

19 Mar 2021

How resistant is the SARS-CoV-2 Brazilian variant to antibodies?

Researchers based at the University of Oxford, UK, have shown that the P.1 Brazilian variant of SARS-CoV-2 is less resistant to natural or vaccine acquired antibody responses than the B.1.351, South African, variant, despite sharing convergent mutations.

18 Mar 2021

Researchers explore potential role of TARM1 protein in pathogenesis of rheumatoid arthritis

TARM1 is a receptor protein whose role in the functioning of the immune system is unknown. In a new study, scientists from Japan have explored the potential role of TARM1 in the pathogenesis of rheumatoid arthritis by analyzing mouse models.

17 Mar 2021

Living with a COVID-19 case brings worse symptoms and stronger antibody response

This study suggests that high virus exposure levels contribute to greater disease severity and stronger antibody responses. The observations from this study are published on the medRxiv preprint server.

17 Mar 2021

Salivary IgG to SARS-CoV-2 after mild COVID-19

A team of researchers based in Stockholm, Sweden, has demonstrated that individuals exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have antibodies for the disease up to nine months after acquiring the disease, even if they displayed only mild symptoms.

16 Mar 2021

Saliva-based testing as a method for monitoring population immunity to SARS-CoV-2 infection

Researchers in the United States have shown that saliva-based sampling could serve as an accurate and non-invasive alternative to blood sampling for monitoring people’s antibody responses following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or vaccination against the virus.

16 Mar 2021

Why does convalescent plasma therapy for severe COVID-19 show mixed success?

A surprising new preprint, released on the medRxiv* server, suggests that the beneficial effects of convalescent plasma (CP) in this disease stem not only from the presence of neutralizing antibodies, but also the immunomodulatory effects of this plasma that shapes the host immune response.

15 Mar 2021

Study maps crucial component of long-term immune response to SARS-CoV-2

Researchers in the United States have found that protective antibodies generated against the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)– the agent that causes coronavirus disease 2019 (COVID-19) – also protect against viral variants.

14 Mar 2021

Could horse-derived antibodies promote immunity against SARS-CoV-2 infection?

Researchers based in India have demonstrated that horses inoculated with an inactivated dosage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are able to produce large amounts of strong antibodies that can neutralize multiple variants

12 Mar 2021

Single-dose vaccines may provide sufficient immunization for individuals previously infected with SARS-CoV-2

A group of researchers based at the Papa Giovanni XXIII hospital in Italy have submitted evidence to suggest that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may adequately benefit from a single dose of mRNA vaccine, rather than requiring the current two-vaccine regimen.

12 Mar 2021

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

In a study published in the journal Drugs, a researcher tackled the approval of Pfizer-BioNTech’s COVID-19 vaccine, which has now been used in many countries.

12 Mar 2021

Immunoglobulin News and Research

New study may shed light on inflammatory bowel disease

Study observes correlation between COVID-19 mortality and autoantibodies in corticosteroid treated patients

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

Reduced mRNA COVID-19 vaccine response in nursing home residents

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

Study suggests SARS-CoV-2 antibodies in breast milk are robust, neutralizing and durable

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

New proteomics method helps confirm COVID-19 transmission from mother to fetus

How resistant is the SARS-CoV-2 Brazilian variant to antibodies?

Researchers explore potential role of TARM1 protein in pathogenesis of rheumatoid arthritis

Living with a COVID-19 case brings worse symptoms and stronger antibody response

Salivary IgG to SARS-CoV-2 after mild COVID-19

Saliva-based testing as a method for monitoring population immunity to SARS-CoV-2 infection

Why does convalescent plasma therapy for severe COVID-19 show mixed success?

Study maps crucial component of long-term immune response to SARS-CoV-2

Could horse-derived antibodies promote immunity against SARS-CoV-2 infection?

Single-dose vaccines may provide sufficient immunization for individuals previously infected with SARS-CoV-2

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News